Recombinant Human TCEAL7 protein

**Background of TCEAL7 Recombinant Protein**

TCEAL7 (Transcription Elongation Factor A-like 7) is a member of the TCEAL family, a group of nuclear proteins implicated in transcriptional regulation and chromatin remodeling. Encoded by the *TCEAL7* gene located on the X chromosome, this protein contains a conserved TEA/ATTS DNA-binding domain, suggesting its potential role in modulating gene expression. While the precise molecular function of TCEAL7 remains under investigation, studies associate it with cellular processes such as differentiation, apoptosis, and tumorigenesis.

Recombinant TCEAL7 protein is engineered using heterologous expression systems (e.g., *E. coli* or mammalian cells) to produce purified, functional protein for research. Its recombinant form enables mechanistic studies, including protein-protein/DNA interactions, post-translational modifications, and pathway analysis. TCEAL7 has garnered attention in cancer biology due to its context-dependent roles. For instance, it acts as a putative tumor suppressor in ovarian cancer, where its downregulation correlates with poor prognosis, while in breast cancer, overexpression may drive oncogenic signaling via pathways like Wnt/β-catenin or p53.

Notably, TCEAL7’s involvement in stress responses and epigenetic regulation highlights its broader biological relevance. However, conflicting reports on its pro- or anti-tumor effects underscore the need for further research to clarify its molecular targets and regulatory networks. Recombinant TCEAL7 serves as a critical tool in dissecting these complexities, offering insights into its therapeutic potential in cancers and other diseases linked to transcriptional dysregulation.